Genistein Exerts Anti-proliferative Effects by Regulating Apoptosis and Autophagy-Related Genes and MicroRNAs in Human Urinary Bladder Neoplasm EJ138 Cells: An Experimental and Bioinformatic Study
Open Access
- 22 February 2025
- journal article
- Published by Brieflands in Iranian Journal of Pharmaceutical Research
- Vol. 24 (1) , e157853
Abstract
Background: Bladder cancer (BC) is the most prevalent urogenital malignancy. Recently, the combination of natural compounds with chemotherapeutic agents has gained attention. Genistein, a natural flavonoid, exhibits anti-cancer properties and represents a promising candidate for treating various cancerous cells due to its cytotoxic potential and minimal adverse effects. Objectives: This study aimed to evaluate the anti-cancer effects of genistein by regulating potential target genes and microRNAs involved in apoptosis and autophagy in EJ138 BC cells. Methods: EJ138 BC cells were treated with different concentrations of genistein, and cell viability was assessed using the MTT assay. To determine the apoptotic rate of EJ138 BC cells following genistein treatment, flow cytometry with Annexin V/PI staining was performed. Additionally, real-time PCR was conducted to analyze the expression of miR-27a, miR-151, apoptotic genes (caspase-3, caspase-9), and autophagic genes (ATG12, Beclin1) after 48 hours of genistein treatment. Statistical analysis was carried out using SPSS V.22, with independent t-tests and one-way ANOVA. Results were considered statistically significant at P < 0.05. Results: Our findings demonstrated that genistein inhibited the proliferation, growth, and viability of EJ138 BC cells and induced cell death. Real-time PCR results confirmed that genistein significantly upregulated miR-27a (P < 0.01), ATG12 (P < 0.01), Beclin1 (P < 0.05), caspase-3 (P < 0.001), and caspase-9 (P < 0.0001), while downregulating miR-151 expression (P < 0.05). Conclusions: The results of this study suggest that genistein suppresses the proliferation and growth of human BC cells by modulating genes and microRNAs involved in apoptosis and autophagy. Therefore, genistein may serve as a novel therapeutic agent for BC treatment.Keywords
This publication has 30 references indexed in Scilit:
- The STRING database in 2023: protein–protein association networks and functional enrichment analyses for any sequenced genome of interestNucleic Acids Research, 2022
- UALCAN: An update to the integrated cancer data analysis platformNeoplasia, 2022
- Genistein: An Integrative Overview of Its Mode of Action, Pharmacological Properties, and Health BenefitsOxidative Medicine and Cellular Longevity, 2021
- Contrast effects of autophagy in the treatment of bladder cancerExperimental Biology and Medicine, 2020
- Targeting apoptotic caspases in cancerBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2020
- Clinical characteristics of colorectal cancer patients and anti-neoplasm activity of genisteinBiomedicine & Pharmacotherapy, 2020
- The global burden of urinary bladder cancer: an updateWorld Journal of Urology, 2019
- Soy Isoflavone Genistein-Mediated Downregulation of miR-155 Contributes to the Anticancer Effects of GenisteinNutrition and Cancer, 2015
- Genistein downregulates onco-miR-1260b and upregulates sFRP1 and Smad4 via demethylation and histone modification in prostate cancer cellsBritish Journal of Cancer, 2014
- Role of the Crosstalk between Autophagy and Apoptosis in CancerJournal of Oncology, 2013